DEBRA

Jan 16, 2020

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

Nov 27, 2018

Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)

Oct 20, 2018

TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa

Feb 26, 2018

TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa

Oct 27, 2017

Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America

Oct 27, 2017

BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa (EB)

Jun 12, 2017

Tarix Orphan Granted Orphan Drug Status by the EMA for TXA127 as Potential Treatment for Epidermolysis Bullosa (EB)

Jun 05, 2017

Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex